European CHMP issues positive opinion recommending approval of license extension for Soliris (eculizumab)
European Medicines Agency - EMA
European Medicines Agency
26 July 2019
CHMP has recommended approval of eculizumab for neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.